v3.25.2
GOODWILL AND INTANGIBLE ASSETS
 6 Months Ended
Jun. 28, 2025
Goodwill and Intangible Assets Disclosure [Abstract]  
GOODWILL AND INTANGIBLE ASSETS GOODWILL AND INTANGIBLE ASSETS
Goodwill

Changes in the carrying amount of goodwill, by reportable segment, were as follows (in millions):
December 31, 2024ImpairmentsCurrency translation adjustmentsJune 28, 2025
CSCA(1)
$2,076.1 $— $9.6 $2,085.7 
CSCI(2)
1,244.1 (1.2)150.6 1,393.5 
Total goodwill$3,320.2 $(1.2)$160.2 $3,479.2 
(1) We had accumulated goodwill impairments of $6.1 million as of June 28, 2025 and December 31, 2024.
(2) We had accumulated goodwill impairments of $997.1 million and $995.9 million as of June 28, 2025 and December 31, 2024, respectively.

Richard Bittner Business Goodwill

On March 10, 2025, the Company signed a definitive agreement to sell the Richard Bittner Business to HBI Health & Beauty Innovations Limited. As a result, we determined an impairment indicator existed and prepared a quantitative goodwill impairment test. We determined the carrying value of this business exceeded the fair value and recorded an impairment charge of $1.2 million within our CSCI segment during the three months ended March 29, 2025. On April 11, 2025, we completed the sale of the Richard Bittner Business to HBI Health & Beauty Innovations Limited (refer to Note 3 and Note 9).
Intangible Assets

Intangible assets and related accumulated amortization consisted of the following(1) (in millions):
 June 28, 2025December 31, 2024
 GrossAccumulated
Amortization		GrossAccumulated
Amortization
Indefinite-lived intangibles:
Trademarks, trade names, and brands$3.6 $— $3.3 $— 
In-process research and development1.9 — 1.9 — 
Total indefinite-lived intangibles$5.5 $— $5.2 $— 
Definite-lived intangibles:
Distribution and license agreements and supply agreements$106.8 $64.8 $101.9 $59.5 
Developed product technology, formulations, and product rights351.7 239.1 341.5 227.2 
Customer relationships and distribution networks1,901.3 1,255.3 1,750.6 1,112.3 
Trademarks, trade names, and brands2,570.6 813.2 2,301.5 672.8 
Non-compete agreements2.1 2.1 2.1 2.1 
Total definite-lived intangibles$4,932.5 $2,374.5 $4,497.6 $2,073.9 
Total intangible assets$4,938.0 $2,374.5 $4,502.8 $2,073.9 
(1) Certain intangible assets are denominated in currencies other than U.S. dollar; therefore, their gross and net carrying values are subject to foreign currency movements.

During the three months ended June 28, 2025, we identified an impairment indicator related to our Prevacid® definite-lived intangible asset in our CSCA segment. The indicator related to expected long-term decline in contribution margin. We determined a fair value assessment of the asset was required. The assessment resulted in an asset impairment of $1.5 million (refer to Note 9).

We recorded amortization expense of $56.6 million and $111.4 million for the three and six months ended June 28, 2025, respectively, and $57.5 million and $115.9 million for the three and six months ended June 29, 2024, respectively.